Prime-CAR Inspection: Enhancing Cancer-Directed CAR-T Cells with Safety-Validated CRISPR Prime Editors

在primer - car Inspection中，我将释放CRISPR引物编辑（PE）的潜力，这是一种具有前所未有的多功能性的新型变革性CRISPR基因编辑平台，用于精确设计癌症导向的CAR-T细胞。PE可以安装所有的单核苷酸变化、小缺失和插入，而无需诱导DNA双链断裂（DSB）或需要DNA模板。PE是精确编辑CAR-T细胞的理想选择，而不会冒着与传统CRISPR/Cas9基因编辑相关的DNA dsb的不良后果。然而，据我所知，由于PE的发展，目前还没有PE工程CAR-T细胞产品。目前，德国的体育专业知识有限。艾美·诺特项目是实现科学独立的绝佳项目。我的目标是成功建立一个Emmy Noether集团，并应用先进的PE概念和最先进的分子方法来生产安全验证的PE工程CAR-T产品（prime -CAR-T）。为此，我将(1)快速开发安装无dsb的半胚型和不含PE的TGF-ß和PD-1变体的Prime-CAR-T原型，利用我在博士后期间开发的分子方法ONE-seq验证PE的基因组安全性，并对Prime-CAR-T产品进行深入的体内外分析。接下来，我将(2)利用pe引导的重组分析靶向CAR转移，通过整合位点分析验证基因组安全性（在我的博士工作中广泛应用），并在细胞和小鼠模型中系统评估CAR- t产品。最后，我将(3)利用文库方法和下一代测序，在超过10,000个免疫相关位点平行地对原代人T细胞中的PE进行高通量分析，加速PE对原代T细胞和潜在的其他car靶向细胞的适应。Prime-CAR Inspection的主要目标是实现PE在CAR-T疗法中令人难以置信的潜力，并为其临床转化铺平道路。建议的工作计划是战略性的结构和雄心勃勃的设计，以确保快速产出和对患者和科学界的高影响，但它也提供了一个独立的，富有成效的和可持续的研究计划的轨迹。我将继续在德国开发PE和安全验证技术。我之所以选择w<s:1> rzburg作为研究地点，是因为我受到了Universitätsklinikum w<e:1> rzburg的翻译免疫治疗项目的鼓舞，这与我的研究目标高度协同。我评估了w<s:1> rzburg的研究环境，发现它是最大限度地支持和最适合进行Prime-CAR检查和后续研究。我带来了一个由国际合作者组成的网络，并且已经开始与w<s:1> rzburg的合作者建立一个网络。Prime-CAR Inspection将使PE适应CAR-T细胞工程和治疗，目标是改善癌症患者的临床护理和预后。

In Prime-CAR Inspection, I will unleash the potential of CRISPR prime editing (PE), a novel and transformative CRISPR gene editing platform with unprecedented versatility, to precision-engineer cancer-directed CAR-T cells. PE can install all single nucleotide changes, small deletions, and insertions without inducing DNA double-strand breaks (DSB) or requiring a DNA template. PE is ideal to precision-edit CAR-T cells without risking undesired consequences of DNA DSBs associated with conventional CRISPR/Cas9 gene editing. However, to my knowledge, PE-engineered CAR-T cell products do not yet exist due to PE's recent development. PE expertise in Germany is currently limited. The Emmy Noether Program is excellent for attaining scientific independence. I aim to successfully establish an Emmy Noether group and apply advanced PE concepts and state-of-the-art molecular methods to generate safety-validated PE-engineered CAR-T products (Prime-CAR-Ts). To do this, I will (1) rapidly develop Prime-CAR-T prototypes installing DSB-free hypomorphic and PE-exclusive TGF-ß and PD-1 variants, validate PE's genomic safety with oligonucleotide enrichment and sequencing (ONE-seq), a molecular method I developed in my postdoc, and in-depth analyze Prime-CAR-T products in vitro and in vivo. Next, I will (2) profile targeted CAR transfer using PE-guided recombination, validate genomic safety with integration site analysis (extensively applied in my doctoral work), and systematically evaluate CAR-T products in cell and mouse models. Finally, I will (3) high-throughput profile PE in primary human T cells at more than 10,000 immune-relevant sites in parallel using library approaches and next-generation sequencing, accelerating PE's adaptation to primary T cells and potentially other CAR-targetable cells. The key ambition of Prime-CAR Inspection is to materialize PE's incredible potential for CAR-T therapy and to pave the way for its clinical translation. The suggested work program is strategically structured and ambitiously designed to ensure rapid output and high impact to the benefit of patients and the scientific community, but it also provides a trajectory to an independent, productive, and sustainable research program. I will continue developing PE and safety validation technology in Germany. I selected Würzburg as the research site because I felt inspired by the impressive work of the translational immunotherapy program at the Universitätsklinikum Würzburg, which is highly synergistic with my research ambitions. I assessed the Würzburg research environment and found it to be maximally supportive and optimally suited to conduct Prime-CAR Inspection and follow-up research. I bring a network of international collaborators and have already started to form a network with collaborators in Würzburg. Prime-CAR Inspection will enable the adaptation of PE to CAR-T cell engineering and therapy with the goal of improving clinical care and outcomes for cancer patients.